The current pipeline of OncoBone Therapeutics includes four therapeutic assets that are co-developed with original inventors of the assets. In addition, several potential assets are under evaluation.
Click the to find out more about the therapeutic asset of each partner
OBP-001 is a first-in-class humanized immunomodulating antibody that has provided proof-of-concept for inhibiting breast cancer lung metastasis. OncoBone Therapeutics will study proof-of-concept for bone metastasis, followed by regulatory safety studies and finding an outlicensing partner for the asset.
OBP-002 is a first-in-class small molecule enzyme inhibitor with good pharmacological profile. Proof-of-concept studies are to be conducted, followed by regulatory safety studies and finding an outlicensing partner for the asset.
OBP-003 is a humanized antibody for a target that is an important regulator of tumor immune escape. Proof-of-concept studies for bone metastasis are to be conducted, followed by regulatory safety studies and finding outlicensing partner for the asset.
OBP-004 is a small-molecule inhibitor that has demonstrated preliminary efficacy for bone metastases in a preclinical study. Proof-of-concept studies for bone metastasis are to be conducted, followed by regulatory safety studies and finding outlicensing partner for the asset.
